Contract

Director – Clinical Quality Assurance

Contractor

Alumis

Alumis

201-500 employees

Develops precision therapies for immune diseases

Compensation Overview

$193k - $242k/yr

+ Stock option grants + Annual bonus

San Bruno, CA, USA

Hybrid

On-site Tuesday-Thursday required.

Bachelor's, Master's

Category
QA & Testing (1)
Required Skills
FDA Regulations

Get referred to Alumis

See people who can refer or advise you

Requirements
  • Bachelor’s or advanced degree in Biology, Chemistry, or related field.
  • Minimum 10 years of ICH-GCP/GVP Quality Assurance experience.
  • Experience with auditing (e.g. Investigator Sites, Clinical Trial Vendors, Processes).
  • Strong understanding of small molecule products with direct experience in solid oral dosage forms.
  • Extensive knowledge of FDA regulations and practices, ICH guidance, and strong knowledge of global health authority regulations and practices.
  • Hands-on experience in drug life cycle management.
  • A successful track record of working with service providers and CROs.
  • Ability to make timely and sound quality decisions when faced with complex clinical, compliance, technical and regulatory considerations. Highly skilled in the ability to work with ambiguity and complexity.
  • Knowledge of Quality Management Systems; experience in implementing and managing quality systems in the pharmaceutical industry.
  • Excellent verbal and written communication skills.
  • Collaborative, analytical and interpretative skills.
  • Ability to work with minimal supervision, to set priorities to meet timelines, to motivate and influence others. Prior management experience is required.
  • Previous experience in successfully leading assigned activities within cross-functional teams.
  • Approximately 15% travel required.
  • Location: South San Francisco, CA onsite Tuesday-Thursday.
Responsibilities
  • Establish and maintain the ICH-GCP Clinical QA programs, policies, and procedures.
  • Ensure ongoing clinical programs are in compliance with applicable health authority regulations, guidelines and internal Standard Operating Procedures.
  • Act as the primary ICH-GCP Clinical QA subject matter expert and point of contact for all ICH-GCP/GVP related matters and issues for the assigned studies and initiatives.
  • Establish/maintain the study specific audit plan; perform audits and lead a team of external quality auditors as needed.
  • Represent Quality on project teams, Health Authority Inspections, service providers and CROs operational meetings, and Clinical QA to Clinical QA meetings.
  • Provide quality oversight and review of key Clinical and IND/NDA enabling documents.
  • Perform reviews of clinical trial documentation for data integrity and compliance with Good Clinical Practice guidance and regulations. Conduct root cause analysis for recurring issues.
  • Support inspection readiness, plans and activities. Act as the primary liaison with Health Authority and internal/external business partners for the assigned studies and programs.
  • Support clinical service provider selection and qualification activities and develop periodic compliance/metric reports.

Alumis develops precision therapies for immune-mediated diseases. By using genetic and disease biology insights, it designs targeted treatments and selects the right targets, molecules, indications, patient groups, endpoints, and possible combinations to optimize outcomes. The company differentiates itself by aligning therapy development with genetic and immunologic understanding to match medicines to the patients who will benefit most. Its goal is to improve clinical outcomes by bringing precision therapies to market and pursuing partnerships or licensing to support development and commercialization.

Company Size

201-500

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2021

Get referred to Alumis

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 13, 2026 results kept the envudeucitinib psoriasis NDA on track for Q4 2026.
  • Deep Track Capital bought 6.77 million shares in Q1 2026, validating the pipeline.
  • June 30, 2026 cash reached $502.3 million, funding operations into Q4 2027.

What critics are saying

  • Q2 2026 revenue fell to $1.7 million while net loss widened to $142.2 million.
  • Lonigutamab impairment and strategic review signal damaged asset value after the ACELYRIN merger.
  • Single-asset dependence on envudeucitinib makes a Q4 2026 NDA failure existential.

What makes Alumis unique

  • Envudeucitinib combines TYK2 inhibition with late-stage psoriasis and lupus programs in 2026.
  • Alumis pairs oral immunology assets with CNS-penetrant A-005 for Parkinson's and multiple sclerosis.
  • The 2025 ACELYRIN merger created a broader immune-mediated diseases platform under one management team.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Unlimited Paid Time Off

Remote Work Options

Commuter Benefits

Phone/Internet Stipend

Gym Membership

Stock Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
Associated Press
Aug 13th, 2026
Alumis' envudeucitinib achieves 54% complete skin clearance in psoriasis trial, NDA submission planned Q4 2026

Alumis reported second quarter 2026 financial results, highlighting that 54% of patients achieved complete skin clearance in its ONWARD3 trial for envudeucitinib in plaque psoriasis after 48 weeks. The company remains on track to submit a New Drug Application to the FDA for the treatment in Q4 2026. The biopharmaceutical firm anticipates potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in systemic lupus erythematosus in Q3 2026. Alumis plans to initiate a Phase 2 biomarker trial for A-005, its CNS-penetrant TYK2 inhibitor, in Parkinson's disease patients in the first half of 2027. As of 30 June 2026, Alumis held cash, cash equivalents and marketable securities of $502.3 million. Research and development expenses decreased to $85.3 million from $108.8 million year-over-year. Net loss was $142.2 million for the quarter.

Intellectia AI
May 25th, 2026
Deep Track Capital Acquires Significant Stake in Alumis

- **Stake Acquisition**: Deep Track Capital disclosed a purchase of 6,772,595 shares of Alumis in Q1 2026, valued at approximately $169.31 million, in...

Yahoo Finance
May 24th, 2026
Deep Track Capital invests $169M in biotech Alumis, up 355% on TYK2 drug pipeline

Deep Track Capital acquired 6,772,595 shares of Alumis (NASDAQ:ALMS) during the first quarter of 2026, an estimated $169.31 million investment based on quarterly average pricing, according to a 15 May SEC filing. The biotechnology company develops therapies for autoimmune and neuroinflammatory diseases. Its lead candidate, envudeucitinib, showed strong Phase 3 psoriasis results with PASI 90 response rates of 68.0% and 62.1% by Week 24. Alumis plans to submit an NDA in the fourth quarter, whilst pivotal Phase 2b lupus data are expected in the third quarter. Alumis shares were trading at $22.02, up 355% over the past year, outperforming the S&P 500's 28% gain. The company held $569.5 million in cash as of quarter-end, sufficient to fund operations into the fourth quarter of 2027.

Yahoo Finance
May 15th, 2026
Major healthcare investor cuts Alumis stake by $10.3M despite stock's 327% surge

Omega Fund Management sold 411,968 shares of Alumis in the first quarter, reducing its stake to 241,255 shares, according to an SEC filing. The transaction was valued at approximately $10.3 million based on quarterly average pricing. Despite the sale, Alumis remains a meaningful holding for Omega at 3.3% of assets under management. The move appears to be profit-taking following Alumis shares' 327% gain over the past year, significantly outperforming the S&P 500's roughly 25% increase. Alumis, a clinical-stage biotechnology company developing therapies for autoimmune diseases, recently reported positive late-stage psoriasis data for its lead TYK2 inhibitor candidate. The company plans an FDA submission in the fourth quarter and ended the quarter with $569.5 million in cash, sufficient to fund operations into late 2027.

Yahoo Finance
May 10th, 2026
ACT Capital's $4M Alumis stake eyes TYK2 inhibitor with 65% psoriasis clearance rate

ACT Capital Management has acquired 174,250 shares of Alumis for approximately $4.36 million, establishing a new position representing 3.02% of its assets under management, according to an SEC filing dated 8 May 2026. The clinical-stage biotechnology company focuses on autoimmune and neuroinflammatory disorders, with lead candidates targeting TYK2 inhibition. Alumis shares have surged 350% over the past year to $23.76, driven by positive Phase 3 data showing 65% of patients achieving PASI 90 skin clearance in plaque psoriasis trials. The company plans to submit a new drug application in the second half of 2026 and expects pivotal Phase 2b lupus data in the third quarter. Alumis raised $345 million in January and held $308.5 million in cash at year-end, despite posting a $243 million net loss.